Journal rankings · indicator year 2025
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Domain ranking · 2025
Health Sciences journal rankings 2025
5,406 ranked journals · Domain
Health Sciences has 5,406 ranked journals in 2025. The median journal has an OJR of 0.69, below the world average of 1.00, unchanged on 2024; Q1 starts at OJR 1.10. The three highest-scoring journals with stable ranks are CA A Cancer Journal for Clinicians, New England Journal of Medicine, and Nature Reviews Disease Primers: each is likely ranked within the top 50.
Ranks and citation indicators: 2025. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2022–2024, the window the 2025 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Fields in Health Sciences (5)
Up to All journals5,406 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. The small range under it is the likely rank range: in 95% of 1,000 resamples of the journal’s papers, it ranked inside that range. Journals whose ranges overlap are not clearly different. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2024. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2022–2024, the window the 2025 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2022–2024 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2016 to 2025. A label compares the 2022→2025 change with the median change of the journal’s field or domain. Rising needs a relative change of +10% or more that is at least 2 standard errors above zero; Falling needs -9.1% or less (rounded), at least 2 standard errors below zero. Sorting uses that relative change. | Compare |
|---|---|---|---|---|---|---|---|
Rank 1; likely between #1 and #1 of 5,406CA A Cancer Journal for CliniciansOAWiley · United States | 116.27Q1 | 505.84 229.09 up from 2024 | 78 | 100% | $4,330 | ||
Rank 2; likely between #2 and #5 of 5,406New England Journal of MedicineMassachusetts Medical Society · United States | 12.85Q1 | 34.58 2.47 up from 2024 | 2,504 | 16% | — | ||
Rank 3; likely between #2 and #7 of 5,406Nature Reviews Disease PrimersNature Portfolio · United Kingdom | 12.51Q1 | 72.06 17.61 up from 2024 | 134 | 17% | — | ||
Rank 4; likely between #2 and #7 of 5,406The LancetElsevier BV · Netherlands | 12.10Q1 | 27.15 1.04 up from 2024 | 2,684 | 36% | $7,890 | ||
Rank 5; likely between #2 and #10 of 5,406Endocrine ReviewsOxford University Press · United States | 10.95Q1 | 26.30 0.11 down from 2024 | 97 | 75% | $3,750 | ||
Rank 6; likely between #4 and #8 of 5,406Nature MedicineNature Portfolio · United States | 10.80Q1 | 33.21 0.42 up from 2024 | 1,446 | 55% | $12,690 | ||
Rank 7; likely between #5 and #11 of 5,406Journal of Hematology & OncologyOABioMed Central · United Kingdom | 9.48Q1 | 32.16 1.95 up from 2024 | 397 | 100% | $4,990 | Rising vs field, 2022–25 | |
Rank 8; likely between #5 and #14 of 5,406Clinical Microbiology ReviewsAmerican Society for Microbiology · United States | 9.01Q1 | 21.99 0.70 down from 2024 | 108 | 100% | — | ||
Rank 9; likely between #6 and #13 of 5,406Cancer CellCell Press · Netherlands | 8.99Q1 | 38.39 10.90 up from 2024 | 541 | 57% | $10,400 | Rising vs field, 2022–25 | |
Rank 10; likely between #6 and #15 of 5,406CirculationLippincott Williams & Wilkins · United States | 8.59Q1 | 25.08 2.29 up from 2024 | 1,319 | 5% | — | Rising vs field, 2022–25 | |
Rank 11; likely between #8 and #17 of 5,406Periodontology 2000Wiley · United Kingdom | 7.80Q1 | 18.47 0.28 up from 2024 | 203 | 81% | $4,430 | ||
Rank 12; likely between #8 and #24 of 5,406The Lancet NeurologyElsevier BV · Netherlands | 7.33Q1 | 19.32 1.22 up from 2024 | 622 | 33% | $7,280 | ||
Rank 13; likely between #10 and #22 of 5,406Nature Reviews Clinical OncologyNature Portfolio · United Kingdom | 7.20Q1 | 36.39 4.12 up from 2024 | 368 | 12% | — | Rising vs field, 2022–25 | |
Rank 14; likely between #2 and #70 of 5,406Implementation ScienceOABioMed Central · United Kingdom | 7.07Q1 | 10.73 3.92 down from 2024 | 225 | 100% | $3,390 | ||
Rank 15; likely between #12 and #19 of 5,406Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 7.00Q1 | 19.67 0.55 down from 2024 | 1,511 | 47% | — | ||
Rank 16; likely between #12 and #28 of 5,406The Lancet Diabetes & EndocrinologyElsevier BV · Netherlands | 6.57Q1 | 14.49 3.74 down from 2024 | 460 | 39% | $7,280 | ||
Rank 17; likely between #15 and #29 of 5,406The Lancet OncologyElsevier BV · United Kingdom | 6.16Q1 | 18.11 0.35 up from 2024 | 865 | 23% | $7,280 | ||
Rank 18; likely between #13 and #37 of 5,406The Lancet. Gastroenterology & hepatologyElsevier BV · United Kingdom | 6.09Q1 | 15.18 2.28 down from 2024 | 546 | 34% | $7,280 | Rising vs field, 2022–25 | |
Rank 19; likely between #15 and #31 of 5,406MMWR Morbidity and Mortality Weekly ReportOACenters for Disease Control and Prevention · United States | 5.97Q1 | 16.46 1.77 down from 2024 | 713 | 100% | — | Falling vs field, 2022–25 | |
Rank 20; likely between #14 and #38 of 5,406Progress in Retinal and Eye ResearchElsevier BV · Netherlands | 5.94Q1 | 16.65 1.64 up from 2024 | 126 | 67% | $6,710 | ||
Rank 21; likely between #15 and #37 of 5,406Journal of HepatologyElsevier BV · Denmark | 5.88Q1 | 18.77 2.17 up from 2024 | 1,172 | 10% | $5,500 | ||
Rank 22; likely between #10 and #52 of 5,406Cancer DiscoveryAmerican Association for Cancer Research · United States | 5.80Q1 | 16.92 6.58 down from 2024 | 543 | 30% | — | ||
Rank 23; likely between #4 and #303 of 5,406Journal of Mixed Methods ResearchSAGE Publishing · United States | 5.79Q1 | 4.13 4.32 down from 2024 | 73 | 30% | $3,900 | ||
Rank 24; likely between #17 and #35 of 5,406Journal of the American College of CardiologyElsevier BV · United States | 5.77Q1 | 13.27 1.07 down from 2024 | 1,603 | 79% | $7,166 | ||
Rank 25; likely between #13 and #56 of 5,406Current Obesity ReportsSpringer Science+Business Media · United States | 5.64Q1 | 18.43 5.00 up from 2024 | 120 | 62% | $5,790 | Rising vs field, 2022–25 | |
Rank 26; likely between #17 and #47 of 5,406Translational NeurodegenerationOABioMed Central · China | 5.46Q1 | 16.98 0.58 up from 2024 | 175 | 100% | $2,990 | Rising vs field, 2022–25 | |
Rank 27; likely between #19 and #45 of 5,406Molecular NeurodegenerationOABioMed Central · United Kingdom | 5.43Q1 | 18.00 1.60 up from 2024 | 255 | 100% | $3,090 | ||
Rank 28; likely between #16 and #54 of 5,406European Heart JournalOxford University Press · United Kingdom | 5.35Q1 | 15.89 2.06 up from 2024 | 2,108 | 13% | $5,922 | ||
Rank 29; likely between #18 and #49 of 5,406Diabetes CareAmerican Diabetes Association · United States | 5.34Q1 | 16.28 2.29 up from 2024 | 1,270 | 86% | — | ||
Rank 30; likely between #8 and #222 of 5,406Journal of Medicine Surgery and Public HealthOAElsevier BV | 5.29Q1 | 14.25 12.25 up from 2024 | 167 | 100% | $1,900 | ||
Rank 31; likely between #22 and #50 of 5,406Medical Image AnalysisElsevier BV · United Kingdom | 5.15Q1 | 17.25 1.42 up from 2024 | 845 | 47% | $4,170 | Rising vs field, 2022–25 | |
Rank 32; likely between #22 and #49 of 5,406The Lancet Digital HealthOAElsevier BV · United Kingdom | 5.13Q1 | 18.66 1.39 down from 2024 | 351 | 100% | $6,680 | ||
Rank 33; likely between #19 and #52 of 5,406GutBMJ · United Kingdom | 5.11Q1 | 13.54 2.14 down from 2024 | 821 | 47% | — | ||
Rank 34; likely between #5 and #561 of 5,406Journal of the National Cancer CenterOAElsevier BV · China | 5.06Q1 | 18.92 10.03 up from 2024 | 129 | 100% | $2,160 | ||
Rank 35; likely between #19 and #61 of 5,406European UrologyElsevier BV · Switzerland | 5.04Q1 | 15.82 2.42 up from 2024 | 559 | 15% | $5,250 | ||
Rank 36; likely between #25 and #47 of 5,406npj Digital MedicineOANature Portfolio · United States | 5.03Q1 | 21.65 3.13 up from 2024 | 786 | 100% | $4,090 | ||
Rank 37; likely between #23 and #55 of 5,406AutophagyTaylor & Francis · United States | 4.89Q1 | 16.03 3.40 up from 2024 | 499 | 99% | — | ||
Rank 38; likely between #20 and #67 of 5,406Journal of the National Comprehensive Cancer NetworkNational Comprehensive Cancer | 4.88Q1 | 13.42 0.76 down from 2024 | 561 | 20% | — | ||
Rank 39; likely between #26 and #55 of 5,406Nature CancerNature Portfolio · United States | 4.84Q1 | 16.64 2.22 down from 2024 | 468 | 41% | $12,690 | Rising vs field, 2022–25 | |
Rank 40; likely between #20 and #66 of 5,406HepatologyLippincott Williams & Wilkins · United States | 4.82Q1 | 16.27 1.50 up from 2024 | 988 | 26% | $2,900 | Rising vs field, 2022–25 | |
Rank 41; likely between #27 and #55 of 5,406JAMA NeurologyAmerican Medical Association · United States | 4.79Q1 | 12.37 0.54 up from 2024 | 684 | 52% | — | ||
Rank 42; likely between #27 and #56 of 5,406Seminars in Cancer BiologyElsevier BV · United States | 4.77Q1 | 18.57 1.72 up from 2024 | 295 | 30% | $6,060 | Rising vs field, 2022–25 | |
Rank 43; likely between #27 and #58 of 5,406The Lancet Respiratory MedicineElsevier BV · Netherlands | 4.76Q1 | 13.34 0.70 down from 2024 | 535 | 42% | $7,280 | ||
Rank 44; likely between #28 and #56 of 5,406DrugsAdis, Springer Healthcare · New Zealand | 4.72Q1 | 14.94 0.72 down from 2024 | 395 | 40% | $5,990 | Rising vs field, 2022–25 | |
Rank 45; likely between #30 and #65 of 5,406The Lancet Global HealthOAElsevier BV · Netherlands | 4.51Q1 | 10.46 1.30 up from 2024 | 998 | 100% | $6,680 | ||
Rank 46; likely between #11 and #380 of 5,406Meta-RadiologyOAElsevier BV | 4.43Q1 | 18.23 7.81 down from 2024 | 52 | 100% | $0 listed | ||
Rank 47; likely between #38 and #59 of 5,406Cardiovascular DiabetologyOABioMed Central · United Kingdom | 4.39Q1 | 15.86 4.29 up from 2024 | 1,073 | 100% | $4,290 | Rising vs field, 2022–25 | |
Rank 48; likely between #28 and #72 of 5,406MetabolismElsevier BV · United States | 4.38Q1 | 16.10 3.92 up from 2024 | 422 | 37% | $5,340 | Rising vs field, 2022–25 | |
Rank 49; likely between #29 and #80 of 5,406Human Reproduction UpdateOxford University Press · United Kingdom | 4.35Q1 | 19.77 1.61 up from 2024 | 108 | 72% | $4,490 | Rising vs field, 2022–25 | |
Rank 50; likely between #32 and #77 of 5,406Nature Reviews Gastroenterology & HepatologyNature Portfolio · United Kingdom | 4.35Q1 | 20.05 1.39 up from 2024 | 432 | 17% | — |
464 Health Sciences journals are labelled rising: their OJR moved up between 2022 and 2025 clearly faster than the median journal of their field or domain.
A journal is rising when its OJR grew from 2022 to 2025 faster than the median journal of its field (or domain, when the field is small), by two tests: the relative change is +10% or more, and it is at least 2 standard errors above zero. So the range of the change at 2 standard errors stays above zero, though not necessarily above +10%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the low end of the range, so the surest rises come first.
- 1Delaware Journal of Public HealthGeneral Health Professions+507% vs groupOJR 0.15 → 0.86range +225% to +1,035%
- 2Journal of the Pediatric Orthopaedic Society of North AmericaOASurgery+326% vs groupOJR 0.11 → 0.44range +189% to +527%
- 3HIV/AIDS - Research and Palliative CareOAInfectious Diseases+235% vs groupOJR 0.35 → 1.09range +166% to +322%
- 4Structural HeartOACardiology and Cardiovascular Medicine+255% vs groupOJR 0.29 → 0.96range +160% to +384%
- 5Clinical and Experimental Obstetrics & GynecologyOAObstetrics and Gynecology+231% vs groupOJR 0.11 → 0.33range +151% to +338%
- 6Access MicrobiologyOAInfectious Diseases+183% vs groupOJR 0.19 → 0.50range +126% to +254%
- 7Daehan nae'si'gyeong bog'gang'gyeong oe'gwa haghoeji/Journal of minimally invasive surgeryOASurgery+330% vs groupOJR 0.14 → 0.57range +125% to +722%
- 8Public Health ActionOAInfectious Diseases+220% vs groupOJR 0.27 → 0.79range +120% to +365%
- 9Neurosurgical Focus VideoOANeurology+212% vs groupOJR 0.11 → 0.32range +109% to +365%
- 10Translational Cancer ResearchOAPulmonary and Respiratory Medicine+124% vs groupOJR 0.25 → 0.51range +102% to +149%
- 11Journal of Translational Internal MedicinePulmonary and Respiratory Medicine+168% vs groupOJR 0.99 → 2.48range +101% to +256%
- 12Advances in respiratory medicineOAPulmonary and Respiratory Medicine+212% vs groupOJR 0.40 → 1.16range +100% to +389%
- 13Journal of ISAKOS Joint Disorders & Orthopaedic Sports MedicineOASurgery+172% vs groupOJR 0.57 → 1.45range +99% to +273%
- 14AIDS Research and TherapyOAInfectious Diseases+154% vs groupOJR 0.55 → 1.31range +98% to +226%
- 15Annals of MedicineOASurgery+123% vs groupOJR 0.85 → 1.78range +88% to +165%
- 16Journal of Clinical AnesthesiaSurgery+120% vs groupOJR 0.79 → 1.62range +86% to +160%
- 17The Korean Journal of Thoracic and Cardiovascular SurgeryOASurgery+141% vs groupOJR 0.24 → 0.54range +81% to +221%
- 18Journal of the International AIDS SocietyOAInfectious Diseases+106% vs groupOJR 0.89 → 1.71range +78% to +138%
- 19AIDS CareInfectious Diseases+102% vs groupOJR 0.37 → 0.70range +74% to +135%
- 20Journal of the International Association of Providers of AIDS Care (JIAPAC)OAInfectious Diseases+149% vs groupOJR 0.51 → 1.19range +73% to +259%
No-label zone, -9.1% to +10%Group median changeBar scale -92% to +1,100% (ratio scale)
461 Health Sciences journals are labelled falling: their OJR moved between 2022 and 2025 clearly behind the median journal of their field or domain.
A journal is falling when its OJR changed from 2022 to 2025 by less than the median journal of its field (or domain, when the field is small), by two tests: the relative change is -9.1% or less (rounded), and it is at least 2 standard errors below zero. So the range of the change at 2 standard errors stays below zero, though not necessarily below -9.1%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the high end of the range, so the surest falls come first.
- 1Revista Latino-Americana de EnfermagemOAGeneral Health Professions-68% vs groupOJR 1.97 → 0.62range -73% to -61%
- 2SN Comprehensive Clinical MedicineSurgery-69% vs groupOJR 0.72 → 0.21range -80% to -51%
- 3Journal of Radiology Case ReportsOASurgery-69% vs groupOJR 0.70 → 0.20range -81% to -50%
- 4Topics in Spinal Cord Injury RehabilitationPathology and Forensic Medicine-64% vs groupOJR 1.55 → 0.52range -76% to -48%
- 5Pharmacy PracticeOAGeriatrics and Gerontology-63% vs groupOJR 1.09 → 0.38range -74% to -47%
- 6Telemedicine Journal and e-HealthPublic Health, Environmental and Occupational Health-55% vs groupOJR 2.23 → 0.93range -64% to -46%
- 7Journal of Health ManagementGeneral Health Professions-66% vs groupOJR 1.61 → 0.53range -79% to -45%
- 8Revista Brasileira de Medicina do EsporteOrthopedics and Sports Medicine-56% vs groupOJR 0.52 → 0.22range -66% to -42%
- 9Open Access Macedonian Journal of Medical SciencesOAPediatrics, Perinatology and Child Health-46% vs groupOJR 0.36 → 0.18range -52% to -40%
- 10Comparative Exercise PhysiologyEquine-61% vs groupOJR 0.43 → 0.16range -74% to -39%
- 11Journal of Cystic FibrosisPulmonary and Respiratory Medicine-50% vs groupOJR 1.20 → 0.56range -59% to -39%
- 12Brazilian Oral ResearchOAPeriodontics-48% vs groupOJR 1.43 → 0.67range -58% to -37%
- 13Journal of Aging & Social PolicyGeneral Health Professions-58% vs groupOJR 4.02 → 1.64range -72% to -37%
- 14Current Medicine Research and PracticeOAPublic Health, Environmental and Occupational Health-78% vs groupOJR 0.74 → 0.15range -93% to -35%
- 15Revista do Colégio Brasileiro de CirurgiõesOASurgery-53% vs groupOJR 0.73 → 0.32range -66% to -34%
- 16Asian Bioethics ReviewPublic Health, Environmental and Occupational Health-55% vs groupOJR 1.93 → 0.82range -69% to -33%
- 17Brazilian Journal of NephrologyOANephrology-55% vs groupOJR 0.61 → 0.26range -70% to -33%
- 18Dermatology Online JournalOADermatology-48% vs groupOJR 0.46 → 0.23range -59% to -33%
- 19Photobiomodulation Photomedicine and Laser SurgeryRadiology, Nuclear Medicine and Imaging-46% vs groupOJR 0.93 → 0.47range -56% to -32%
- 20MedicinesOAPhysiology-50% vs groupOJR 1.55 → 0.72range -64% to -32%
No-label zone, -9.1% to +10%Group median changeBar scale -92% to +1,100% (ratio scale)
Fields of Health Sciences, compared.
Journals
The endpoints below each rank show its likely range. How rank ranges are calculated
Citations made in 2025. Corpus-wide, 84.3% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
949 additional Health Sciences journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2022–2024, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2025. Publication window: 2022–2024. How these summaries are calculated
- Ranked journals
- 5,406
- Window papers (baseline)
- 3,550,948 +6.5% from indicator year 2022
- Median OJR
- 0.69 +1.5% from indicator year 2022
- Rising journals (2025)
- 464
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2022–2024 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 2,007 | 2,150 | 2,285 | 2,374 | 2,486 | 2,626 | 2,757 | 2,922 | 3,062 | 3,193 | 3,364 | 3,591 | 3,809 | 4,129 | 4,361 | 4,544 | 4,757 | 4,979 | 5,239 | 5,390 | 5,462 | 5,563 | 5,606 | 5,618 | 5,549 | 5,406 | |
| Window papers (baseline) | 813,419 | 909,304 | 974,228 | 1,051,248 | 1,094,845 | 1,200,886 | 1,317,521 | 1,455,690 | 1,577,275 | 1,733,757 | 1,887,930 | 2,035,231 | 2,126,669 | 2,204,628 | 2,320,572 | 2,437,477 | 2,534,543 | 2,585,157 | 2,649,222 | 2,728,712 | 2,846,138 | 3,078,764 | 3,332,730 | 3,490,788 | 3,507,496 | 3,550,948 | |
| Median OJR | 0.50 | 0.53 | 0.56 | 0.59 | 0.61 | 0.63 | 0.6778 | 0.70 | 0.726 | 0.748 | 0.767 | 0.773 | 0.78 | 0.741 | 0.76 | 0.750 | 0.737 | 0.727 | 0.71 | 0.725 | 0.735 | 0.680 | 0.67 | 0.6776 | 0.681 | 0.69 |
| Measure | Category statistic | Eligible population |
|---|---|---|
| Journal self-citation share | Median: 3.3% | 4,151 journals |
| Retracted papers per 1,000 | Pooled rate: 1.372 per 1,000 | 4,101 journals |
| Output growth | Median: -6.3% | 5,009 journals |
| Open access share | Median: 100.0% | 5,406 journals |
| Listed APC (USD) | Median including $0 listed prices: $3,090 | 2,959 ranked journals with a known listed price, including $0 listed prices |
| International collaboration share | Median: 20.2% | 5,241 journals |
| Review share | Median: 2.7% | 5,406 journals |
| Articles-only OJR | Median: 0.70 | 5,372 journals |
| Uncited share | Median: 37.7% | 5,406 journals |
| Citation concentration | Median: 46.2% | 5,398 journals |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.